ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
The agreement calls for the use of ANGLE’s custom DNA Damage Response (DDR) tests in a phase I cancer clinical trial overseen by Artios, planned to be completed by the end of 2024.
The partnership has facilitated the development of two distinctive immunofluorescence tests by ANGLE. These tests, using the Parsortix system, identify crucial biomarkers in circulating tumour cells (CTCs).
Traditionally, the availability of tumour tissue biopsy samples was unpredictable and scarce, making it difficult to monitor these biomarkers. However, ANGLE’s tests offer an innovative solution by collecting CTCs from liquid biopsies.
This advanced method allows Artios to assess treatment effects and the pharmacodynamics of new DDR drugs by continually tracking biomarker expression. The successful realization of the DDR tests, an achievement of high sensitivity and specificity, paves the way for their potential application in subsequent, larger clinical trials and possibly other compounds in Artios’ pipeline.
This progress underscores ANGLE’s value to a growing market of drug developers exploring the DDR pathway. Based on clinicaltrials.gov data, there are currently 105 DDR drugs in the pipeline, with about 123,000 patients participating in active trials.
The market capacity is significant, with the worldwide value of DDR treatments expected to increase from $3.5 billion in 2020 to an estimated $24.8 billion by 2030, exhibiting an impressive compound annual growth rate (CAGR) of 21.3%.
Andrew Newland, the Founder and CEO of ANGLE, stated, “These new assays also constitute a significant extension to our pharma services offerings, which has already drawn considerable attention from potential new clients.” No financial specifics were disclosed.
